Healthcare / Medical Instruments & SuppliesStockholm
$81.50
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $99.4M · quality 29.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.6B
P/E
48.2x
↑EV/EBITDA
20.1x
↑ROE
27.5%
↑Gross Margin
68.4%
↑Debt/Equity
1.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+26.6%
FCF CAGR
—
FCF margin
-0.3%
FCF / Net income
-0.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.47B · net income $165.7M · FCF $-8.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.47B | $2.47B | $1.97B | $1.61B | $1.22B |
| Net Income | $165.7M | $165.7M | $145.8M | $104.1M | $48.6M |
| EBITDA | $476.5M | $476.5M | $425.1M | $320.6M | $198.8M |
| EPS | 1.56 | 1.56 | 1.37 | 0.98 | 0.46 |
| Gross Margin | 68.4% | 68.4% | 68.8% | 67.8% | 64.8% |
| Operating Margin | 11.1% | 11.1% | 11.6% | 9.9% | 6.3% |
| Net Margin | 6.7% | 6.7% | 7.4% | 6.5% | 4.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.83 | 1.83 | 1.74 | 2.60 | 2.98 |
| Current Ratio | 1.63 | 1.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.3M | $-8.3M | $99.4M | $142.9M | $-22.0M |
| Returns | |||||
| ROE | 27.5% | 27.5% | 32.1% | 35.0% | 23.1% |
| Valuation | |||||
| P/E | 48.22 | 48.22 | 45.62 | 42.65 | 49.34 |
| EV/EBITDA | 20.12 | 20.12 | 17.16 | 15.80 | 14.65 |
| P/B | 14.41 | 14.41 | 14.63 | 14.96 | 11.36 |
| Growth & Yield | |||||
| Revenue Growth | 25.1% | 25.1% | 22.2% | 32.6% | — |
| EPS Growth | 13.9% | 13.9% | 39.8% | 113.0% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
66.7%
EPS terminal req.
$7.23
Spread vs growth
-52.9%
5Y implied EPS CAGR
41.2%
EPS terminal req.
$8.75
Spread vs growth
-27.3%
10Y implied EPS CAGR
24.6%
EPS terminal req.
$14.09
Spread vs growth
-10.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.5%
Start / end P/E
75.4x → 52.2x
EPS bridge
1.37 → 1.56
Residual
-4.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.